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Jean Pierre Pignon, MD, PhD,† and on behalf of the LACE Collaborative Group
Background: To evaluate the impact of adjuvant cisplatin-vinorelbine
in completely resected non-small cell lung cancer and identify patients
likely to benefit from this regimen in the Lung Adjuvant Cisplatin
Evaluation (LACE) database. The overall LACE meta-analysis showed
survival benefit with cisplatin-based adjuvant chemotherapy (5-year
survival benefit of 5.4%, hazard ratio HR 0.89, p 0.004). Subgroup
analysis for the cisplatin-vinorelbine regimen was prespecified in the
LACE statistical analysis plan. Patients randomized to cisplatin-vinorel-
bine or observation were the largest subgroup (41%) and the most
homogeneous in terms of drug doses and eligibility.
Patients and Methods: The LACE-vinorelbine cohort included trials
evaluating cisplatin-vinorelbine versus observation. Overall survival
was the primary end point. Other studies randomizing patients to other
chemotherapy or observation (LACE-other) were also evaluated.
Results: The LACE-vinorelbine cohort included 1888 patients from
four studies (Adjuvant Navelbine International Trialist Association, Big
Lung Trial, International Adjuvant Lung Cancer Trial, and National
Cancer Institute of Canada Clinical Trials Group JBR.10). Baseline
characteristics were similar to the LACE-other but had fewer patients
with stage IA (2% versus 11%). Survival improvement at 5 years was
8.9% with cisplatin-vinorelbine versus observation (HR 0.80, 95%
confidence interval: 0.70–0.91, p 0.001). Stage was a significant
predictor for survival (test for trend, p 0.02; benefit at 5 years: 14.7%
stage III, 11.6% stage II, and 1.8% stage I). Similar benefits were
seen for disease-free survival (HR 0.75 0.67–0.85, p0.001, stage III
HR 0.62, 0.50–0.76, stage II HR 0.69, 0.57–0.83, and stage I HR
0.95, 0.76–1.19). The overall result was statistically superior to LACE-
other (LACE other HR 0.95, 0.86–1.05, interaction p  0.04).
Conclusion: In subgroup analyses, adjuvant cisplatin-vinorelbine
provides a superior survival benefit and can be recommended in
completely resected stages II and III non-small cell lung cancer.
Key Words: Non-small cell lung cancer, Adjuvant cisplatin-vi-
norelbine, Meta-analysis.
(J Thorac Oncol. 2010;5: 220–228)
Lung cancer is the most frequent cause of cancer deathworldwide.1 Patients with completely resected stage I non-
small cell lung cancer (NSCLC) have a 5-year survival of
60%, whereas it falls to 10% for completely resected stage
III.2,3 The first meta-analysis published in 19954 showed a
nonsignificant 5% survival benefit at 5 years for patients receiv-
ing cisplatin combinations (hazard ratio HR 0.87, p 0.08). In
the following years, doublet combinations of cisplatin with new
agents improved survival in patients with metastatic disease, but
only one of these agents, vinorelbine, has been tested prospec-
tively in combination with cisplatin in randomized adjuvant
trials. Several meta-analyses including newer cisplatin-based
regimens showed a small but consistent effect on survival.5–9
The more recent Lung Adjuvant Cisplatin Evaluation (LACE)10
is a meta-analysis based on individual patient data from the five
largest adjuvant trials of cisplatin-based adjuvant chemotherapy
published after 1995.11–17 LACE showed a HR of 0.89 for death
(95% confidence interval CI: 0.82–0.96, p  0.004) corre-
sponding to an absolute survival benefit of 5.4% at 5 years, in
agreement with the 1995 meta-analysis.10
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Patients randomized to cisplatin-vinorelbine or observa-
tion constituted the largest subgroup (1888 of 4584 patients,
41%) and the most homogeneous in terms of cisplatin dose. A
prospectively planned analysis of chemotherapy effect accord-
ing to regimen in LACE revealed a statistical trend (interaction
p 0.11) for superiority of cisplatin-vinorelbine compared with
the other cisplatin-based doublets with vindesine, vinblastine, or
etoposide and triplet combinations with mitomycin C, ifosf-
amide, or vinblastine. Although not originally planned, the
indirect comparison of cisplatin-vinorelbine to other combina-
tions (pooled) demonstrated a significant interaction (i.e., varia-
tion of the effect of chemotherapy compared with no treatment
according to the type of chemotherapy, p  0.04) in favor of
cisplatin-vinorelbine. We report here the results of these sub-
group analyses.
PATIENTS AND METHODS
Inclusion and Exclusion Criteria
The LACEmeta-analysis has been described previously.10
Briefly, eligible trials (a) were randomized trials performed after
the NSCLC meta-analysis published in 1995, (b) included only
patients with completely resected NSCLC, and (c) compared
cisplatin-based chemotherapy versus no chemotherapy. Trials
were excluded if they (a) used concomitant radiochemotherapy
or preoperative chemotherapy; (b) included incompletely re-
sected patients; and (c) were included in the 1995 NSCLC
meta-analysis. LACE prospectively planned evaluation of treat-
ment effect according to types of chemotherapy received (cis-
platin-vinorelbine, other cisplatin-based doublets, or triplets).
Trials included in LACE comparing cisplatin-vinorelbine
with observation were included in the LACE-vinorelbine cohort
and included Adjuvant Navelbine International Trialist Associ-
ation (ANITA), Big Lung Trial (BLT), International Adjuvant
Lung Cancer Trial (IALT), and JBR.10. All other trials or strata
within trials were pooled into a “LACE-other” subgroup and
were compared with the LACE-vinorelbine subgroup.
Analyses
For LACE-vinorelbine, the primary objective was overall
survival. Secondary objectives were (a) interaction between
predefined baseline covariates and the effect of cisplatin-vinorel-
bine; (b) cause-specific mortality; (c) disease-free survival
(DFS); and (d) chemotherapy-related severe toxicity. Each trial
was analyzed individually, and all data were pooled for the
overall analysis. In addition, the results for LACE-vinorelbine
were compared with those for the LACE-other subgroup.
Population
All patients, including ineligible patients, were analyzed
in the group to which they were randomized, independent of the
chemotherapy actually received (intent-to-treat analysis).
Data Checks
As described previously,10 individual patient data were
retrieved for each study. Systematic data checking and reanaly-
sis were performed by the meta-analysis team at Institut Gustave
Roussy.
Statistical Analyses
Times to events were measured from the date of random-
ization. Survival was the time until death of any cause or last
known alive date. DFS was the time until first recurrence or
death of any cause or last disease evaluation date. Second
cancers were not considered as an event, and follow-up was not
censored after a second cancer. Median follow-up was computed
using the reverse Kaplan-Meier method.18
Survival and DFS per treatment group were estimated
using Peto curves19 and their comparison summarized by HRs
stratified by trial with their 95% CIs. The analysis of survival
was based on a log-rank test stratified by trial. Chi-square tests
were used to study heterogeneity among trials and groups. I2
statistic was also used.20 Test of heterogeneity used to compare
the HR of groups of trials is also called test for interaction.
Cause-specific mortality (lung cancer, death from other cause
after a lung cancer recurrence and death from unknown cause
versus nonlung cancer)10 was described by treatment arm and
compared using the log-rank test stratified by trial. As proposed
by Peto,21 data were censored at the first recurrence for nonlung
cancer mortality. The log-rank statistic for nonlung cancer mor-
tality was subtracted from the log-rank statistic for mortality
from all causes to obtain the log-rank statistic of lung cancer
mortality.21 Variations in treatment effect were described using
forest plots of HRs. Multivariate Cox regression analysis was
performed to estimate chemotherapy effect adjusted for pre-
specified factors of age, type of surgery, histology, and stage.
Treatment Compliance and Toxicity
The actual doses of cisplatin and vinorelbine (available for
ANITA, JBR.10, and BLT) and time between surgery and start
of chemotherapy were described. Grade 3, 4, or 5 toxicity was
collected in all trials except IALT, which collected only grades
4 and 5 toxicity. Toxicities were not available from the BLT
trial.
LACE Organization
A Steering Committee for LACE was constituted with
one clinician and one statistician from each trial, together with
the two statisticians from the data center in charge of the pooled
analysis (see Appendix). This committee validated the statistical
analysis plan, selected the data to be included in the publication,
and contributed to the writing of the manuscript. All analyses
were performed at the Institut Gustave-Roussy.
Role of the Funding Source
The sponsors of the LACE meta-analyses and these
subgroup analyses had no role in the study design, data
collection, data analysis, data interpretation, or the writing
of the report. The corresponding author had full access to
all data in the study and had final responsibility for the
decision to submit for publication.
RESULTS
Four studies from LACE were eligible for the LACE-
vinorelbine subgroup analyses with a total of 1888 patients
(Tables 1 and 2). Two studies evaluated the cisplatin-vinorel-
bine combination exclusively (ANITA and JBR.10). In the
other two (IALT and BLT), the investigator could choose
among several regimens; each center used only one regimen,
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and patients were randomized by center. Median follow-up
was 5.2 years. The LACE-other subgroup consisted of 2696
patients of whom 1347 received nonvinorelbine but cisplatin-
based chemotherapy (Tables 1 and 2).
Patients aged 70 years were slightly more common in
LACE-vinorelbine (10% versus 8%), and stage IA were more
numerous in LACE-other (11%) than in LACE-vinorelbine
(2%). In both subgroups approximately two thirds of patients
TABLE 1. Overview of Studies Included in the LACE-Vinorelbine and LACE-Other Subgroups
No. of Patients Evaluated and Follow-Up
LACE, N
LACE-Vinorelbine LACE-Other
N
Randomized to
Cisplatin Vinorelbine Follow-Upa (yr) N
Randomized to
Other Chemotherapy Follow-Upa (yr)
ANITA 840 840 407 5.9 0 0 —
IALT 1867 500 248 4.1 1367 684 4.9
JBR.10 482 482 242 5.2 0 0 —
BLT 307 66 37 4.9 241 115 5.2
ALPI 1088 0 0 — 1088 548 5.4
Total 4584 1888 934 5.2 2696 1347 5.2
a Median.
LACE, Lung Adjuvant Cisplatin Evaluation; ANITA, Adjuvant Navelbine International Trialists Association; IALT, International Adjuvant Lung Trial; BLT, Big Lung Trial.
TABLE 2. Patients Characteristics (%)
Characteristics
LACE-Vinorelbine LACE-Other
Chemotherapy
(N  934)
Observation
(N  954)
Chemotherapy
(N  1347)
Observation
(N  1349)
Age (yr)
Median 59 59 60 61
Range 27–81 18–77 27–83 30–79
Sex (%)
Male 79 80 81 81
Female 21 20 19 19
Unknown 1 1 0 0
Pathological TNM stage (%)
IA 3 2 12 11
IB 34 33 26 28
II 37 39 33 33
III 26 26 29 28
Unknown 0 0 1 1
Type of surgery (%)
Pneumonectomy 33 31 27 28
Lobectomy/other 62 65 64 63
Unknown 4 3 9 9
Performance status (%)
0 49 50 31 31
1 47 47 23 24
2 3 2 5 5
Unknown 1 1 41 40
Histologic type (%)
Squamous cell 48 49 49 48
Adenocarcinoma 42 41 39 38
Other 10 10 12 14
Area of the world (%)
Europe 68 68 91 91
North America 26 26 1 1
Other 6 6 8 8
LACE, Lung Adjuvant Cisplatin Evaluation; TNM, tumor, node, metastasis.
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presented with stages II and III. No firm conclusions can be
drawn regarding the distribution of performance status among
subgroups because the data were missing for approximately
40% of patients in LACE-other. The majority of patients in
LACE were evaluated in Europe, and most patients from North
America were in the LACE-vinorelbine subgroup (26% versus
1% in LACE-other) as corresponding mostly to the JBR.10
study. Other baseline variables were similarly distributed be-
tween LACE-vinorelbine and LACE-other.
Effect of Cisplatin-Vinorelbine on Survival
For the LACE-vinorelbine subgroup, 45.3% of cisplatin-
vinorelbine patients had died (versus 53.7% observation) with a
median follow-up of 5.2 years. Patients randomized to adjuvant
FIGURE 1. A, Forest plot of hazard ratios of overall survival and disease-free survival with cisplatin-vinorelbine versus observa-
tion (control). B, Forest plot of hazard ratios of overall survival and disease-free survival with cisplatin-vinorelbine versus obser-
vation (control) according to stage.
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cisplatin-vinorelbine had a 20% reduction in the risk of death
(HR 0.80, 95% CI: 0.70–0.91, p 0.001). The test of hetero-
geneity among trials was not significant (p 0.52) (Figure 1A).
The absolute benefit was 6.8% at 3 years (64.3% versus 57.5%)
and 8.9% at 5 years (55.1% versus 46.2%) (Figure 2A). In the
multivariate Cox model chemotherapy (HR 0.76), squamous
histology (HR 0.69), pneumonectomy (HR 1.33), age (51–60
years, HR 1.26, 61–69, HR 1.40, 70, HR 1.90), and stage
(stage II, HR 1.72; stage III, HR 2.61) were significant prognos-
tic factors. Sex showed a trend for better survival in females
(p  0.07; see Web Table 1, Supplemental Digital Content 1,
http://links.lww.com/JTO/A13). There was a significant interac-
tion of cisplatin-vinorelbine effect and stage (test for trend p 
0.02) (Figure 1B): patients with stage I had no benefit from
chemotherapy (1.2% at 3 years and 1.8% at 5 years),
whereas the effect was significant for stage II (10.5% at 3
years and 11.6% at 5 years) and stage III (11.5% at 3 years
and 14.7% at 5 years) (Figure 3).
The effect on survival was significantly higher (test of
interaction p 0.04) in LACE-vinorelbine (HR 0.80, mentioned
above) compared with LACE-other (HR 0.95, 95% CI: 0.86–
1.05, p  0.33). There was no significant interaction with stage
in LACE-other. In LACE-vinorelbine, no significant interaction
was observed between chemotherapy and covariates of sex,
performance status, age, histology, type of surgery, and planned
radiotherapy, and chemotherapy effect was not different with
planned doses of cisplatin or vinorelbine.
Effect of Cisplatin-Vinorelbine on DFS
A significant difference in DFS was observed for pa-
tients receiving cisplatin-vinorelbine with a HR 0.75 (CI:
0.67–0.85, p  0.001) (Figure 1A). The absolute benefit at 3
years was 10.0% and at 5 years 9.2%. A clear relation
between chemotherapy effect and stage was also observed on
DFS for LACE-vinorelbine, the effect was significant for
stage II: HR 0.69 (CI: 0.57–0.83) and for stage III: HR 0.62
(CI: 0.50–0.76) but not for stage I: HR 0.95 (CI: 0.76–1.19),
test for trend, p  0.008 (Figure 1B).
The effect on DFS was significantly higher (test for
interaction p  0.02) in LACE-vinorelbine compared with
LACE-other (HR 0.90 0.82–0.99], p  0.04). For LACE-
other, the benefit at 5 years was 3.8%. No interaction with
stage was demonstrated (data not shown).
Effect of Cisplatin-Vinorelbine on Compliance
and Toxicity
In the cisplatin-vinorelbine subgroup, 7% of patients
did not receive chemotherapy and 0.6% of patients in the
observation group did. The majority of patients were planned
to receive a total cisplatin dose 400 mg/m2 (Table 3). The
median dose delivered was 303 mg/m2 for cisplatin and 236
mg/m2 for vinorelbine, and the median relative dose intensi-
ties were 95% and 69%, respectively. There were 371 pa-
tients (43%) who did not complete chemotherapy because of
FIGURE 2. A, Survival curves for the cisplatin-vinorelbine
and the observation (no chemotherapy) groups. Absolute
benefit (1 standard deviation). B, Lung cancer-specific and
nonlung cancer-related survival for the cisplatin-vinorelbine
and the observation (no chemotherapy) groups.
FIGURE 3. Overall survival curves by stage for the cisplatin-
vinorelbine versus the observation (no chemotherapy)
groups.
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patient refusal (42%), toxicity (30%), or unknown reasons
(10%). The median time between surgery and initiation of
chemotherapy was 41 days with 6% of patients initiating
chemotherapy more than 2 months after surgery. Twenty
percent of patients in ANITA, 17% in JBR.10, 11% in IALT,
and 41% in BLT received only one cycle of chemotherapy.
For LACE-other, 9% of patients randomized to chemo-
therapy did not receive it, whereas 2% randomized to obser-
vation did. Planned doses of cisplatin were lower than for the
LACE-vinorelbine subgroup (Table 3).
The incidence of grade 3 toxicity was collected in
two of the trials in LACE-vinorelbine (ANITA and
JBR.10), whereas only grades 4 and 5 toxicity were in
IALT. ALPI (LACE-other) collected only toxicity  grade
3. No data were available for BLT. Neutropenia  grade 4
was observed in 55% in LACE-vinorelbine and 10% of
patients in LACE-other, but life threatening or fatal febrile
neutropenia ( grade 4) was 0 in LACE-vinorelbine and
1% in LACE-other. There was no difference in periph-
eral neurotoxicity grade 3. Overall, grades 4  5 toxic-
ities were more frequent in LACE-vinorelbine (59% versus
16% in LACE-other, Table 4).
Effect of Cisplatin-Vinorelbine on Cancer-
Related and Noncancer-Related Deaths
As shown in Table 5, there were 13 (1.4%) reported
drug-related deaths in the cisplatin-vinorelbine arm, mainly
because of septic shock. The drug-related death rate for
LACE-other was 0.4.
When considering the overall follow-up period, in the
LACE-vinorelbine subgroup, noncancer-related death was
not significantly different between the two arms (HR 1.31,
0.91–1.88 p  0.15), whereas there was a highly statisti-
cally significant difference in lung cancer-specific death (HR
0.74 0.65–0.85, p 0.001) (Figure 2B). For LACE-other,
there was a significant increase (p  0.01) in nonlung cancer
deaths (HR 1.40 1.08–1.82).
A significant interaction over time was observed both
for LACE-vinorelbine (p  0.002) and LACE-other (p TA
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TABLE 4. Incidence of Grades 3, 4, and 5 Toxicity and
Therapy-Related Deaths in LACE Other and LACE-Vinorelbine
Toxicity
Vinorelbine Other
Grades
3–5 (%)a
Grades
4–5 (%)b
Grades
3–5 (%)a
Grades
4–5 (%)b
N 599 837 460 1077
Neutropenia 80 55 27 10
Febrile neutropenia 9 0 2 0
Thrombocytopenia 3 1 5 2
Neuropathy 3 0 3 0
Renal impairment 1 0 2 0
Nausea and vomiting 20 3 16 3
Infection 8 2 0 0
Constipation 4 1 1 0
a All studies except BLT and IALT.
b All studies except BLT.
IALT, International Adjuvant Lung Trial; BLT, Big Lung Trial.
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0.03) with a significant increase of nonlung cancer death in
the first 6 months in both groups: 2.92 (1.54–5.51, p 0.001)
for LACE-vinorelbine (29 versus 9 deaths) and 2.17 (1.33–
3.53, p  0.002) for LACE-other (45 versus 20 deaths). In
LACE-vinorelbine, among the 29 early nonlung cancer
deaths observed in the cisplatin-vinorelbine arm, 13 (45%)
were drug related and 12 (41%) related to cardiovascular or
pulmonary disease. There were six cardiovascular or pulmo-
nary deaths in the observation arm of nine early deaths. In
LACE-other, there were six (13%) drug-related deaths and 28
(62%) cardiovascular or pulmonary deaths among the 45
early deaths in the chemotherapy arm. In the corresponding
observation arm, there were 15 cardiovascular or pulmonary
deaths of 20 early deaths.
Use of Adjuvant Postoperative Radiation
Therapy
The impact of postoperative radiation therapy
(PORT) was not assessable in either the LACE-vinorelbine
or the LACE-other analysis, because the use and regimens
of PORT varied among trials and was not mandatory or
randomized. PORT was planned for a similar percentage of
patients in LACE-vinorelbine and LACE-other: 33% and
31% for the observation groups and 30% and 32% in the
chemotherapy groups, respectively.
DISCUSSION
We have evaluated the effect of cisplatin-vinorelbine
on survival in patients with completely resected stages I to
III NSCLC within the LACE database. Baseline charac-
teristics of the patients in the trials evaluating this combi-
nation were similar to those included in the other LACE
trials, except for a slightly lower incidence of stage IA and
a predominance of patients from North America.
Survival of patients receiving cisplatin-vinorelbine
was statistically superior to observation (absolute benefit
8.9% at 5 years) and was also statistically superior to the
benefit observed in LACE-other (overall test for interac-
tion p  004). Baseline characteristics were similar and
could not account for these results. In LACE-vinorelbine,
stage was a strong predictor. Patients with stage IIIA
benefited the most, closely followed by patients with stage
II. Too few patients with stage IA were treated with
cisplatin-vinorelbine to make a definitive interpretation,
whereas in stage IB (approximately 34% of the total
group), cisplatin-vinorelbine did not affect outcomes,
when compared with observation. In LACE-other, there
was no variation of treatment effect with stage, although a
significant effect was observed in stage IB for DFS (HR
0.75, 95% CI: 0.60–0.93) and a borderline effect for
survival (HR 0.81, 95% CI: 0.64–1.02). These results are
in agreement with the Cancer and Leukemia Group B 9633
trial using paclitaxel-carboplatin in stage IB showing a
significant benefit on failure-free survival but no signifi-
cant difference on overall survival.22 However, in the
updated NSCLC meta-analysis of 30 trials and 8147 pa-
tients, no interaction with stage was observed.23 Thus, the
absence of an effect of chemotherapy in stage I with
cisplatin-vinorelbine reported here should be interpreted
with caution.
Although the planned cisplatin dose was higher in
LACE-vinorelbine than LACE-other, the median dose of
cisplatin delivered in LACE-vinorelbine was lower than in-
tended and close to the median dose delivered with other
cisplatin doublets but higher than that delivered with cisplatin
triplets in LACE.10
Toxicity observed with the cisplatin-vinorelbine regi-
men was as expected for the combination, and was higher in
LACE-vinorelbine than in LACE-other, in particular for
grade 4 neutropenia (80% grade3). The incidence of febrile
neutropenia grade 4 was similar in LACE-vinorelbine and
LACE-other. Overall reported grade 3 toxicity was ob-
served in 90% of patients receiving cisplatin-vinorelbine
versus 49% in LACE-other. There seemed to be a small
increase in chemotherapy-related deaths in LACE-vinorel-
bine compared with LACE-other (1.4% versus 0.4%). It
should be noted that these data are difficult to interpret
because ANITA and JBR.10 collected laboratory and toxicity
data in a more rigorous fashion than other trials. A quantifi-
cation of differences in tolerability between cisplatin-vinorel-
bine and other regimens evaluated in LACE was not an
objective of the meta-analysis and cannot be addressed ade-
quately. However, in the IALT study, vinorelbine was asso-
ciated with a higher grades 4 to 5 toxicity rate than other
associated drugs with an odds ratio adjusted on region of the
world and received dose of cisplatin at first cycle of 2.5
(1.7–3.7) for vinorelbine versus other (A. Dunant et al.,
personal communication).
TABLE 5. Causes of Death
Cause of Death
LACE-Vinorelbine LACE-Other
Chemotherapy
(N  934)
Observation
(N  954)
Chemotherapy
(N  1347)
Observation
(N  1349)
Total no. of deathsa 423 (45.3) 512 (53.7) 713 (52.9) 742 (55.0)
No. of lung cancer deaths (%)b 354 (83.7) 464 (90.6) 579 (81.2) 651 (87.7)
No. of nonlung cancer deaths (%)b 69 (16.3) 48 (9.4) 134 (18.8) 91 (12.3)
No. of drug- related deaths (%)c 13 (1.4) 6 (0.4)
a Percentage of the total number of patient randomized in the corresponding arm.
b Percentage of the total number of deaths in the corresponding arm.
c Included in the nonlung cancer deaths.
LACE, lung adjuvant cisplatin evaluation.
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The excess of early nonlung cancer deaths described in
LACE10 was found in both LACE-vinorelbine and LACE-
other. Possible explanations for this unexpected effect have
been discussed previously and were mainly related to che-
motherapy toxicity and lethal cardiopulmonary events.10
Addition of PORT to adjuvant chemotherapy with
cisplatin-vinorelbine could not be assessed. A descriptive
analysis in the ANITA trial suggested a possible benefit in
patients with N2 disease, whereas patients with N1 disease
experienced a potential detrimental effect.24 The role of
PORT in N2 disease is presently being evaluated in the
randomized Lung Adjuvant Radiation Therapy trial.
Cisplatin-vinorelbine is the only third generation drug in
combination with cisplatin tested so far to demonstrate a signif-
icant survival benefit with a reduction in the risk of death of 20%
versus observation, despite an increase in toxicity. Indirect
comparison with other cisplatin-based combinations (3–8% re-
duction) is in favor of cisplatin-vinorelbine. Based on these
results, the evidence supports the selection of cisplatin-vinorel-
bine as the adjuvant chemotherapy of choice for patients with
completely resected stages II and IIIA.
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